 |
Hot Pursuit
25-Jun-24
|
|
|
|
|
|
|
|
|
|
|
|
Cipla gets VAI classification from USFDA for Patalganga facility
|
|
Cipla said that US Food and Drug Administration (USFDA) classified the inspection conducted at Patalganga, Maharashtra facility as Voluntary Action Indicated (VAI).
|
|
|
|
|
|
Earlier on 4 April 2024, the USFDA had the routine current good manufacturing practices (cGMP) inspection at the company’s Patalganga manufacturing facility.
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.
The pharma company reported 79% jump in consolidated net profit to Rs 939.04 crore on 10% increase in revenue from operations to Rs 6,163 core in Q4 FY24 over Q4 FY23.
Shares of Cipla shed 0.15% to Rs 1,501 on the BSE.
|
|
|
|
Previous News |
Cipla to table results
(
Corporate News
-
03-Oct-24
10:15
)
|
|
|
Nifty scales above 26,050; IT shares advance
(
Market Commentary
-
Mid-Session
26-Sep-24
10:37
)
|
|
|
Cipla’s UK arm inks pact to acquire 6.9124% stake in Cipla Jiangsu Pharmaceuticals
(
Hot Pursuit
-
26-Sep-24
10:27
)
|
|
|
Cipla to acquire JV partners' 6.91% in Cipla Jiangsu
(
Corporate News
-
25-Sep-24
17:38
)
|
|
|
Cipla Ltd up for third consecutive session
(
Hot Pursuit
-
11-Sep-24
13:06
)
|
|
|
Cipla announces board meeting date
(
Corporate News
-
04-Sep-24
17:50
)
|
|
|
Cipla vice-chairman M.K. Hamied resigns
(
Hot Pursuit
-
04-Sep-24
08:56
)
|
|
|
Board of Cipla approves change in directorate
(
Corporate News
-
03-Sep-24
18:49
)
|
|
|
Cipla Ltd spurts 1.99%, rises for fifth straight session
(
Hot Pursuit
-
30-Aug-24
13:00
)
|
|
|
Cipla Ltd up for five straight sessions
(
Hot Pursuit
-
12-Aug-24
13:00
)
|
|
|
Cipla Ltd gains for third straight session
(
Hot Pursuit
-
08-Aug-24
13:05
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|